Galmed pharmaceuticals announces publication in "the journal of autoimmunity" for its ind ready, amilo-5mer, a specific anti-inflammatory compound

Tel aviv, israel, aug. 19, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the publication in the journal of autoimmunity for its ind ready compound, amilo-5mer entitled: "mtadv 5-mer peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-serum amyloid a.
GLMD Ratings Summary
GLMD Quant Ranking